Verapamil and Alzheimer’s Disease: Past, Present, and Future
Open Access
- 5 May 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 562
Abstract
Verapamil is a phenylalkylamine class calcium channel blocker that for half a century has been used for the treatment of cardiovascular diseases. Nowadays, verapamil is also considered as a drug option for the treatment of several neurological and psychiatric disorders, such as cluster headache, bipolar disorders, epilepsy, and neurodegenerative diseases. Here, we review insights into the potential preventive and therapeutic role of verapamil on Alzheimer’s disease (AD) based on limited experimental and clinical data. Pharmacological studies have shown that verapamil has a wide therapeutic spectrum, including antihypertensive, anti-inflammatory, and antioxidative effects, regulation of the blood-brain barrier function, due to its effect on P-glycoprotein, as well as adjustment of cellular calcium homeostasis, which may result in the delay of AD onset or ameliorate the symptoms of patients. However, the majority of the AD individuals are on polypharmacotherapy, and the interactions between verapamil and other drugs need to be considered. Therefore, for an appropriate and successful AD treatment, a personalized approach is more than necessary. A well-known narrow pharmacological window of verapamil efficacy may hinder this approach. It is therefore important to note that the verapamil efficacy may be conditioned by different factors. The onset, grade, and brain distribution of AD pathological hallmarks, the time-sequential appearances of AD-related cognitive and behavioral dysfunction, the chronobiologic and gender impact on calcium homeostasis and AD pathogenesis may somehow be influencing that success. In the future, such insights will be crucial for testing the validity of verapamil treatment on animal models of AD and clinical approaches.Keywords
Funding Information
- Ministerio de Ciencia, Innovación y Universidades
- European Regional Development Fund
This publication has 149 references indexed in Scilit:
- P-Glycoprotein Function at the Blood–Brain Barrier: Effects of Age and GenderMolecular Imaging and Biology, 2012
- Reproducibility of quantitative (R)-[11C]verapamil studiesEJNMMI Research, 2012
- Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's diseaseJournal of Pharmacy and Pharmacology, 2011
- Verapamil protects dopaminergic neuron damage through a novel anti-inflammatory mechanism by inhibition of microglial activationNeuropharmacology, 2011
- L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's diseaseNeurobiology of Disease, 2011
- Calcium Signaling and Amyloid Toxicity in Alzheimer DiseaseJournal of Biological Chemistry, 2010
- Enhanced Calcium Buffering in F344 Rat Cholinergic Basal Forebrain Neurons Is Associated With Age-Related Cognitive ImpairmentJournal of Neurophysiology, 2009
- Neuronal calcium mishandling and the pathogenesis of Alzheimer's diseaseTrends in Neurosciences, 2008
- Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the storeAging Cell, 2007
- 15-year longitudinal study of blood pressure and dementiaThe Lancet, 1996